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Rare Elizabethkingia anophelis meningitis case in a Danish male
Hans Linde Nielsen,1,2,* Irene Harder Tarpgaard,1 David Fuglsang-Damgaard,1 Philip Kjettinge Thomsen,1
Sylvain Brisse3 and Michael Dalager-Pedersen4
Abstract
Introduction. Elizabethkingia anophelis is a Gram-negative, aerobic, non-motile rod belonging to the family Flavobacteriaceae.
Over the last 5 years, it has emerged as an opportunistic human pathogen involved in neonatal meningitis and sepsis, as
well as nosocomial outbreaks. It has been isolated from the midgut of the Anopheles gambiae mosquito, but there is no
evidence for a role of the mosquito in human infections, and very little is known regarding the routes of transmission to
humans. Recent studies, primarily from South-East Asia, suggest that E. anophelis, and not Elizabethkingia meningoseptica, is
the predominant human pathogen of this genus. However, identification to the species level has been difficult due to the
limitations of the current MALDI-TOF MS (matrix-associated laser desorption ionization-time of flight MS) systems for
correct species identification.
Case presentation. Here, we present a rare case of E. anophelis meningitis in a Danish male, who had a travel exposure to
Malaysia 7 weeks before hospitalization. A multidrug-resistant Elizabethkingia species was isolated from blood and
cerebrospinal fluid, and genomic sequencing was used to characterize the phylogenetic position of the isolate, which was
determined as associated with previously described sublineage 11. The patient was successfully treated with intravenous
moxifloxacin and rifampicin for 2 weeks with no major sequelae, but we did not find the source of transmission.
Conclusion. All clinical microbiologists should be aware of the present limitations of the MALDI-TOF MS systems for correct
species identification, and therefore we recommend the use of genome sequencing for the correct identification at the
species and sublineage level.
INTRODUCTION
Elizabethkingia is a genus of Gram-negative, aerobic, non-
motile rods first proposed in 2005 by Kim et al. [1], belong-
ing to the family Flavobacteriaceae. Elizabethkingia species
are considered ubiquitous in nature; however, very little is
known regarding the routes of transmission of Elizabethkin-
gia to humans [2, 3]. The original genus consisted of Eliza-
bethkingia meningoseptica and Elizabethkingia miricola.
E. meningoseptica is presumably the most recognized spe-
cies causing hospital-acquired infections, including sepsis in
immunocompromised patients and neonatal meningitis [4],
whereas E. miricola is increasingly being isolated from
human infections similar to those caused by E. meningosep-
tica, as well as septic arthritis [5].
In 2011, Elizabethkingia anophelis was isolated from the
midgut of the Anopheles gambiae mosquito [6]. In 2013,
Frank et al. reported the first case of E. anophelis infection
in humans, which occurred in the Central African Republic
and involved an 8-day-old female with neonatal meningitis,
which was considered as nosocomially acquired [7]. The
authors confirmed the identification of E. anophelis by 16S
rRNA sequencing. Sequencing of a second strain from
another case of neonatal meningitis from 2006, which was
originally identified as E. meningoseptica, subsequently
revealed that this strain was in fact E. anophelis [7, 8].
Shortly after the first report, several cases of E. anophelis
infection have been reported from Hong Kong and Taiwan
[9, 10], and E. anophelis is now recognized as the dominant
Elizabethkingia species found in blood cultures [11]. More-
over, two extensive outbreaks have occurred in the
Midwestern USA involving 65 cases, with a case fatality rate
of 31% (20/65). The majority of patients had bloodstream
infections, but some had E. anophelis isolated from other
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sites, such as their respiratory systems or joints (https://
www.cdc.gov/elizabethkingia/outbreaks/) [12].
A common feature for E. anophelis infection involves a high
percentage of healthcare-associated infections, including
sepsis/meningitis in neonates, or cases of sepsis in adults
with underlying medical conditions including malignancies,
diabetes and chronic obstructive pulmonary disease. Here,
we present a rare case of E. anophelis meningitis in a Danish
male, who had a travel exposure to Malaysia 7 weeks before
hospitalization.
CASE REPORT
A 76-year-old Danish male presented to the emergency
department at Aalborg University Hospital (Aalborg,
Denmark) in May 2017 with right-side otalgia throughout
the previous week, and onset of fever and confusion within
the previous 24 h. Upon admission, the patient was other-
wise healthy, and he used no daily medication. Fifty-three
days prior to admission, the patient returned from a 16 day
holiday on the east coast of Peninsular Malaysia. Before the
journey, he was re-vaccinated against diphtheria, tetanus
and hepatitis A. He had not used malaria prophylaxis dur-
ing his vacation.
On examination, the patient had altered mental status with
a Glasgow Coma Score of six, neck stiffness and fever
(40.0

C). In accord with national guidelines on the manage-
ment of suspected bacterial meningitis, the patient had
blood cultures performed and was started on high-dose
intravenous (iv) benzylpenicillin (1.8 g every 4 h), cefotax-
ime (3 g every 6 h) and dexamethasone (10mg every 6 h). A
lumbar puncture of the patient was performed, following a
computed tomographic scan of the cerebrum, which had
proved normal. Laboratory tests showed a C-reactive-pro-
tein level of 273mg l 1, procalcitonin of 10.8 µg l 1 and
white blood cells of 19.9109 l 1. Cerebrospinal fluid (CSF)
analysis revealed pleocytosis with white blood cells of
741106 l 1 (636 polynuclear and 105 mononuclear), a
slightly decreased glucose ratio (CSF : serum) of 0.38, an ele-
vated protein level of 1.34 g l 1 and lactate of 7.3mmol l 1,
and the patient was transferred to the Intensive Care Unit
(ICU).
Overnight culture of the patient’s CSF yielded Gram-nega-
tive, non-motile, oxidase- and catalase-positive rods. More-
over, a simultaneous positive blood culture (BD BACTEC;
Becton Dickinson) had similar findings. MALDI-TOF MS
(matrix-associated laser desorption ionization-time of flight
MS) (MALDI Biotyper 3.1, Bruker Daltonics Microflex LT,
MBT 6903 MSP Library) could not distinguish the colonies
between either E. meningoseptica (score 2.215) or E. miri-
cola (score 2.101), whereas E. anophelis was not present in
the MALDI library. API 20 E v5.0 (bioMerieux) gave an
identification of E. meningoseptica with a score of 71.6%
identity (numerical profile: 0042004). The isolate was multi-
drug resistant and positive for metallo-b-lactamase by using
the MBL Confirm kit (Rosco Diagnostica). Antimicrobial-
susceptibility testing (AST) was performed by using Etests
(bioMerieux) according to the European Committee on
Antimicrobial Susceptibility Testing guidelines (http://www.
eucast.org). We used the pharmacokinetics/pharmacody-
namics (non-species related) breakpoints except for tri-
methoprim/sulfamethoxazole, in which Stenotrophomonas
maltophilia breakpoints were used, and for gentamicin and
colistin we used Pseudomonas species breakpoints, as per-
formed by Eriksen et al. [5]. The isolate was susceptible to
moxifloxacin (MIC 0.125mg l 1) and trimethoprim/sulfa-
methoxazole (MIC 0.25mg l 1); intermediately susceptible
to amoxicillin/clavulanic acid (MIC 6mg l 1); and resistant
to ciprofloxacin (MIC 0.75mg l 1) and all other drugs
tested including: ampicillin, cefuroxime, ceftazidime, mero-
penem, gentamicin, colistin and tigecycline. An Etest for
vancomycin showed a MIC of 12mg l 1, but we did not
make an interpretation of susceptible or resistant. Etests
were not available for piperacillin/tazobactam and rifampi-
cin, but the disc diffusion zone (Neo-Sensitabs; Rosco Diag-
nostica) for piperacillin/tazobactam was 19mm and for
rifampicin was 24mm, but as for vancomycin we did not
make an interpretation of susceptible or resistant.
To determine the identity of the isolate to the species level,
we performed sequencing with the Illumina MiSeq instru-
ment producing 2300 bp paired-end reads by using a Nex-
tera XT library preparation kit (Illumina). Reads were
assembled using CLC Genomics Workbench (version 11)
(QIAGEN Bioinformatics) into 105 contigs, N50 (497, 160),
total sequence length 4 047 726 bp, with a G+C content of
35.6mol%.
Analysis of the 16S rRNA gene, as well as a k-mer based dis-
tance measure, compared to the publicly available strains of
E. meningoseptica and E. miricola showed a clear identifica-
tion of the isolate as E. anophelis (data not shown). Breurec
et al. [3] and Perrin et al. [12] reported a clear division of
E. anophelis into 15 sublineages, including 1 associated with
the large outbreak of E. anophelis infections that occurred in
Wisconsin (USA) in 2015–2016. To subtype our strain and
define its sublineage, we used the core-genome multilocus
sequence typing (cgMLST) strategy, using the subset of
1546 genes families that are highly conserved within
E. anopheles [3]. The cgMLST profile of our isolate was
compared to those publicly available in the Elizabethkingia
cgMLST database on the Institut Pasteur server (http://
bigsdb.pasteur.fr/elizabethkingia/). Cluster analysis based
on cgMLST profiles, see Fig. 1, showed that the isolate
belonged to sublineage 11, which was defined with strain
CIP 60–59 (CDC 3375; ATCC 13255; NCTC 10586; CCUG
4321; LMG 12873) as a reference. Strain CIP 60–59 was iso-
lated from the CSF of a premature infant who died [13];
however, the two strains of sublineage 11 have different
alleles at 299 loci out of 1513 loci called in both strains. This
result clearly shows that AAUH 98722 (our isolate) and CIP
60–59 are genetically distinct. The assemblies were submit-
ted to ResFinder 3.0 (http://cge.cbs.dtu.dk/services/Res-
Finder/) to analyse them for the presence of antimicrobial-
resistance genes [14]. The isolate proved positive for two
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metallo-b-lactamase genes, namely blaGOB-3 (located on
contig 69; hit length 756; 100% ID; accession no.
AF189291), and blaB-3 (located on contig 21; hit length 750;
100% ID; accession no. AF189299), as well as an extended-
spectrum b-lactamase-encoding gene, blaCME-1, (located on
contig 41; hit length 784; 100% ID; accession no.
AJ006275). This is consistent with the known conservation
of carbapenemase and b-lactamase-encoding genes within
E. anophelis [3, 12, 15, 16].
After the preliminary identification of Elizabethkingia spe-
cies, the antimicrobial therapy was changed to iv vancomy-
cin combined with iv rifampicin, 600mg two times a day.
However, as MICs values were available the day after, the
definite treatment was changed to iv moxifloxacin, 400mg
once per day, combined with iv rifampicin 600 mg two
times a day for a total duration of 14 days. The patient
improved and after 10 days at the ICU he was transferred to
the infectious disease ward for further treatment and reha-
bilitation, and he was finally discharged after 3 weeks of
hospitalization. The only sequela was a partial hearing loss.
Due to the severity of infection, the patient was examined
for immunodeficiency in an outpatient setting and was
found to have a sustained and elevated level of IgM of
approximately 14 g l 1 (normal range 0.39–2.1 g l 1) during
the following months. Seven months after the meningitis
episode, his bone marrow was further investigated, and he
was finally diagnosed with lymphoplasmacytic lymphoma
(Waldenström macroglobulinaemia).
DISCUSSION
Little is known regarding the routes of transmission of
E. anophelis, and despite investigations by the CDC in the
Midwestern USA outbreaks, no potential sources or routes
of disease transmission were identified [12]. Our patient
Fig. 1. Dendrogram of the E. anophelis strains available on the Institut Pasteur server generated by use of BIGSdb software (http://
bigsdb.pasteur.fr/elizabethkingia/). The tree was obtained using the UPGMA algorithm based on cgMLST allelic profiles. The scale rep-
resents the proportion of loci with distinct alleles among the 1546 gene loci. Our isolate (AAUH 98722) was shown to belong to subline-
age 11, which was defined with strain CIP 60-59.
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had a travel exposure to Malaysia more than 7 weeks before
hospitalization, so we cannot rule out the small risk of trans-
mission after exposure to Anopheles mosquitoes. However,
a long incubation period of 7 weeks seems very unlikely,
and phylogenetic analysis showed that the strain was not
related to the strains of mosquito midgut origin (Ag1 and
R26), and a local acquisition is probably more likely. The
patient was cured after 2 weeks of iv moxifloxacin and
rifampicin, and suffered a relatively benign sequela in the
form of partial hearing loss. However, as the patient was
diagnosed with lymphoplasmacytic lymphoma 7 months
after his meningitis episode, we cannot rule out that he may
have been immunocompromised at the time of diagnosis of
E. anophelismeningitis.
Previous, correct species identification has been challenged
by the limitations of the commercial systems as well as the
MALDI-TOF MS systems available on the market, which
are unable to identify E. anophelis correctly [2], and there-
fore the latest reports have used 16S rRNA or whole-
genome sequencing for the correct identification [7–10].
Recently, Chew et al. [11] published a species-specific PCR
for the differentiation of E. anophelis and E. meningoseptica,
and it may prove useful in high-epidemic areas like South-
East Asia and East Asia.
Our E. anophelis isolate was multidrug resistant with pro-
duction of metallo b-lactamases (blaGOB-3 and blaB-3) con-
ferring resistance to third-generation cephalosporins and
carbapenems. Fortunately, further resistance testing of the
isolate revealed a low MIC to moxifloxacin by Etest and
apparent susceptibility to rifampicin by disc diffusion, and
the patient was treated successfully with this combination of
antibiotics. Levofloxacin, another late-generation fluoro-
quinolone is, in contrast to moxifloxacin, not available as a
treatment option in Denmark. Results from previous studies
have shown some discrepancies in sensitivity to later-gener-
ation fluoroquinolones. In a study from Singapore, Chew
et al. found that 78.5% of 79 isolates from blood were sus-
ceptible to levofloxacin [11], whereas a study from South
Korea by Han et al. determined that 29 and 41% of isolates
were susceptible to levofloxaxcin and moxifloxacin, respec-
tively [17]. Rifampicin was added to the treatment regimen
for our patient, and the South Korean data showed 96%
susceptibility to rifampicin among their isolates of E. ano-
phelis [17]. However, the Asian studies used other AST pro-
tocols and Clinical and Laboratory Standards Institute
interpretations [11, 17], and therefore our AST data is not
directly comparable.
Vancomycin has been used successfully for treatment of
E. meningoseptica bacteraemia [18], and initially, the patient
was treated with iv vancomycin, in combination with rifam-
picin. However, the vancomycin level obtained in CSF may
be suboptimal, and is highly dependent on inflamed menin-
ges, whereas both moxifloxacin and rifampicin have better
CSF penetration that is less dependent on meningeal
inflammation [19]. Trimethoprim/sulfamethoxazole could
also have been a treatment option for our patient, but recent
studies have found variable susceptibility to trimethoprim/
sulfamethoxazole [2, 10, 17]. Moreover, trimethoprim/sulfa-
methoxazole seems to have a higher incidence of adverse
reactions compared to moxifloxacin, and that contributed
to the selection of moxifloxacin and rifampicin as the tar-
geted treatment.
In conclusion, we present a rare case of E. anophelis menin-
gitis in a Danish male. The patient had a travel exposure to
Malaysia 7 weeks before hospitalization; however, by phylo-
genetic analysis and the fact that the isolate belonged to sub-
lineage 11 favours an unknown transmission. The patient
was cured by treatment with iv moxifloxacin and rifampicin
for 2 weeks. All clinical microbiologist should be aware of
the present limitations of the MALDI-TOF MS systems for
correct species identification, and therefore we recommend
genome sequencing for the correct identification at species
and sublineage level.
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